Skip to content

Released Aug 12, 2025, after the close

10-Q filed Aug 12, 2025, 43 days after period end · 0001390478-25-000016

Q2 2025 · 10-Q
Revenue—
Net Income-$6.60MN/M vs Q2 2024N/M vs Q1 2025
EPS Diluted-$0.07N/M vs Q2 2024N/M vs Q1 2025
Operating Income-$6,873,000N/M
Operating Cash Flowderived-$7,330,000N/M

What the release said

The release

Same quarter

MetricQ2 2025Q2 2024Q2 2023Q2 2022
Revenue——$0.00$0.00
Net Income-$6.60M-$7.47M-$8.84M-$8.41M
EPS Diluted-$0.07-$0.13-$0.31-$0.41

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR